Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CODEXIS, INC.CDXS · Entity 6428 | Director | June 17, 2026 | June 18, 2026 |
| Kairos Pharma, LTD.KAPA · Entity 8244 | Director | October 08, 2025 | November 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CODEXIS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17 | Direct | 66,350 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.
Kairos Pharma, LTD.
Report date October 08, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 49,204 |
Reported balance
After 2025-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 19,084 · Balance 49,204 F1: Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2: Consists of 49,204 RSUs which remain subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2: Consists of 49,204 RSUs which remain subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:51 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 66,350 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001610717-26-000268 · form4.xml · derivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,350 Underlying: Common Stock · 66,350 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| October 08, 2025 Filed Nov 26, 2025 22:26 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025203 · ownership.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,204 F1 · shares: Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of 49,204 RSUs which remain subject to vesting. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 23:30 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 40,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002133 · form4.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,052 F1 · shares: The restricted stock units vest as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:27 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 30,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001719 · form4.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,069 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| November 09, 2023 Filed Nov 14, 2023 23:21 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0000905148-23-001447 · form4.xml · derivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-11-09 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on each annual anniversary of the grant date, such that the option will be fully vested and exercisable on November 9, 2027, in each case subject to continued service through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:07 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 34,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000158 · form4.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,949 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 22:59 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 31,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018010 · doc1.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,347 F1 · shares: Restricted Stock. The shares vest as to one third of the shares on each yearly anniversary of the date of grant, provided that the Reporting Person provides continuous services to the Issuer as an employee, consultant, director or officer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.